Estimation of coronary flow reserve by transesophageal coronary sinus Doppler measurements in patients with syndrome X and patients with significant left coronary artery disease  by Zehetgruber, Manfred et al.
JACC Vol. 25, No. 5 1039 
April 1995:1039 45 
Estimation of Coronary Flow Reserve by Transesophageal Coronary 
Sinus Doppler Measurements in Patients With Syndrome X and 
Patients With Significant Left Coronary Artery Disease 
MANFRED ZEHETGRUBER,  MD,  GERALD MUNDIGLER,  MD,  G I ]NTER CHRIST ,  MD,  
DEDDO MORTL ,  CM, PETER PROBST,  MD,  FACC,  HELMUT BAUMGARTNER,  MD,  
GERALD MAURER,  MD,  FACC,  PETER S IOSTRZONEK,  MD 
Vienna, Austria 
Objectives. This study sought to determine the feasibility of 
coronary sinus flow velocity analysis by transesophageal Doppler 
echocardiography for estimation of coronary flow reserve in 
patients with syndrome X and patients with coronary artery 
disease. 
Background. Coronary flow reserve provides useful information 
in patients with coronary artery disease and patients with syn- 
drome X. Current methods of measuring coronary flow reserve are 
invasive or require extensive laboratory equipment, or both. 
Transesophageal Doppler recordings of coronary sinus flow ve- 
locity before and after vasodilator application may allow nonin- 
vasive determination of coronary flow reserve. 
Methods. We obtained coronary sinus flow velocity recordings 
before and after dipyridamole administration (0.6 mg/kg body 
weight per 5 min) in 9 patients with syndrome X, 14 with 
significant left coronary artery disease and 22 age-matched con- 
trol patients. We used the formula anterograde minus retrograde 
flow velocity time integral times heart rate as an index of coronary 
sinus flow. Coronary flow reserve was calculated by dividing 
coronary sinus flow variables after dipyridamole administration 
by the respective baseline values. 
Results. Technically adequate recordings were obtained in 44 
(98%) of 45 patients. Compared with that in the control group 
(2.78 +- 0.95 [mean -+ SD]), coronary flow reserve was signifi- 
cantly lower in patients with syndrome X (1.21 -+ 0.23, p < 0.001) 
as well as in those with coronary artery disease (1.47 - 0.7, p < 
0.001). Using a cutoff coronary flow reserve value of 1.8, sensitiv- 
ity, specificity and overall predictive value of coronary flow reserve 
determinations were, respectively, 100%, 91% and 94% for syn- 
drome X and 86%, 91% and 89% for coronary artery disease. 
Conclusions. Coronary flow reserve calculation by transesoph- 
ageai coronary sinus flow velocity recordings i  feasible in a large 
proportion of patients and might be useful for the noninvasive 
evaluation of patients with syndrome X and patients with severe 
left coronary artery disease. 
(J Am CoU Cardiol 1995;25:1039-45) 
Assessment of coronary flow reserve from myocardial blood 
flow measurements before and after administration of coro- 
nary vasodilators has been shown to provide important diag- 
nostic information in a variety of cardiac diseases (1,2). There 
is particular interest in this variable in patients with syndrome 
X in whom coronary flow reserve is typically impaired. Unfor- 
tunately, methods used for estimation of coronary flow reserve 
are either invasive, time-consuming or require extensive labo- 
ratory staff and equipment (3-7). Therefore, a noninvasive 
widely available method would be desirable. 
We recently proposed the measurement of coronary sinus 
flow velocity by transesophageal Doppler echocardiography 
before and after dipyridamole for the assessment of coronary 
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flow reserve in normal subjects and in patients with dilated 
cardiomyopathy (8). However, the feasibility and diagnostic 
value of this method in patients with syndrome X and in those 
with coronary artery disease has not yet been evaluated. Thus, 
the present study was performed to address the hypothesis that 
the analysis of coronary sinus flow velocity by transesophageal 
Doppler echocardiography before and after dipyridamole pro- 
vides a feasible method for coronary flow reserve stimation in 
patients with syndrome X and in those with extensive left 
coronary artery disease. 
Methods  
Patients. Demographic data of the three study groups are 
presented in Table 1. All patients had normal transthoracic 
echocardiographic results without evidence of valvular disease, 
left ventricular hypertrophy and regional or diffuse wall motion 
abnormalities. 
Group A (syndrome X). Patients meeting the following 
criteria were considered to have syndrome X (9): 1) history of 
typical effort angina, promptly relieved at cessation of activity 
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Table 1. Demographic Data for Three Patient Groups 
Patients With 
Syndrome X Patients With CAD Control Patients 
(n = 9) (n = 14) (n - 22) 
Age (yr) 60 ± 8 54 +- 8 53 -+ 14 
Women/men 5/4 3/11 11/11 
LV mass (g) 170 ± 55 214 ± 17 175 ± 51 
LV EF (%) 74 -+ 8 68 + 12 74 - I2 
LV EDD (ram) 46.2 _+ 6.7 53.2 _+ 6.2 50.2 = 4.3 
Data presented are mean ± SD or number of patients. CAD = coronary 
artery disease; EDD end-diastolic diameter; EF ejection fraction; LV = left 
ventricular. 
or sublingual administration of nitroglycerin, or both; 2) 
normal 12-lead rest electrocardiographic (ECG) findings; 3) 
positive symptom-limited supine bicycle ergometric stress test 
results, with transient horizontal or downsloping ST segment 
depression ->0.1 mV 0.08 s after the J point, with occurrence of 
typical angina was defined as a positive result; and 4) normal 
coronary angiographic findings and a negative response to 
ergonovine administration. Multiple views of the left and right 
coronary artery were reevaluated independently b two expe- 
rienced observers. Absence of coronary artery stenosis as well 
as wall irregularities was unequivocally reconfirmed in all 
patients. Furthermore, patients with a history of smoking, 
hypertension r hypercholesterolemia were excluded. Overall, 
nine patients fulfilled the inclusion criteria. Mean achieved 
work load in these nine patients was (mean _+ SD) 112.5 _+ 
23W (63.5 _+ 24% of the predicted gender-, age- and body 
surface area-corrected physical working capacity). ST segment 
depression (0.1 mV in seven and 0.2 mV in two patients) 
occurred at a mean work load of 87.5 _+ 29.8 W (49.6 _+ 22% 
of the corrected working capacity). Two patients were receiv- 
ing beta-adrenergic blocking agents, three calcium antagonists 
and two long-acting nitrates; two patients had no antianginal 
treatment. 
Group B (coronary artery disease). Group B comprised 14 
consecutive patients with significant (>70%) stenosis of the 
left coronary artery. Patients with left main coronary artery 
stenosis and unstable angina, with occlusion of a major coro- 
nary vessel, or patients with an extensive myocardial infarction 
were excluded. According to severity and location of the lesion, 
patients were classified into two subgroups: group B1 included 
patients with severe (>90%) stenosis of the left anterior 
descending artery proximal to the first septal branch (n = 7) 
with or without additional lesions of the left anterior descend- 
ing coronary artery or of the left circumflex coronary artery. 
Group B2 included patients with less severe (70% to 90%) or 
more distal stenosis, or both, of the left anterior descending 
coronary artery or left circumflex coronary artery (n = 7). 
Using the modified Gensini ndex (10) for estimating severity 
and extent of coronary artery disease, group B1 had a signifi- 
cantly higher index than group B2 (127.8 + 33 vs. 54.7 _+ 13, 
p < 0.0001). Overall, five patients had a history of previous 
myocardial infarction (Q wave infarction in three, non Q wave 
infarction in two). Four patients had intravenous thrombolysis. 
Coronary angiography revealed patency of the infarct-related 
vessel in all cases. Antianginal medication i cluded nitrates in 
11 patients, beta-blockers in 9 and calcium antagonists in 3. 
Group C (control patients). Twenty-two age- and gender- 
matched neurosurgical patients with intended posterior cranial 
fossa surgery and no cardiac disease formed the control group. 
These patients were preoperatively referred for transesopha- 
geal echocardiography to exclude patency of the foramen 
ovale. All patients were free of cardiac symptoms, had a 
normal 12-lead rest ECG as well as normal echocardiographic 
findings. Moreover, patients with cardiovascular risk factors 
were excluded. 
Echocardiography. The study protocol was in accordance 
to the guidelines of the local human subjects committee. 
Informed consent was obtained from all patients. In patients 
with syndrome X, all antiangial medication was withheld for 
>24 hours before the examination. In patients with severe 
symptomatic coronary artery disease, antianginal medication 
was interrupted on the day of the study only. 
The study was performed with a Vingmed 800 system 
(Diasonics) using a 3.25-MHz transthoracic and a single-plane 
5-MHz transesophageal probe. Transthoracic echocardiogra- 
phy comprised all standard views, including a parasternal 
M-mode study of the left ventricle. Measurements of left 
ventricular dimensions, function and mass were performed 
according to standard criteria (11,12). Transesophageal echo- 
cardiography was performed without sedation using topical 
anesthesia tothe oropharynx. Continuous ECG recording was 
performed, and arterial blood pressure was measured nonin- 
vasively at baseline and after dipyridamole administration. 
Recording of coronary sinus flow velocity. A modified four- 
chamber view with dorsal angulation of the transducer was 
used to visualize the ostium of the coronary sinus. The position 
of the probe was optimized until the coronary sinus with its 
ostium into the right atrium could be visualized throughout the 
cardiac cycle. Coronary sinus flow velocity recordings were 
performed with the Doppler sample volume placed in the 
coronary sinus within a distance of no more than 10 mm from 
its ostium (Fig. 1). In all patients the angle between the 
Doppler beam and the long axis of the coronary sinus was 
<30 °. Flow signals were recorded uring prolonged expiration 
and were repeated until constant flow signals of acceptable 
quality were obtained. Maximal coronary sinus diameter was 
measured at baseline and after dipyridamole. 
After baseline recordings, the transducer was maintained in 
the identical position. Dipyridamole was administered intrave- 
nously at a constant infusion rate of 0.6 mg/kg body weight per 
5 rain (13). Two minutes after cessation of dipyridamole 
infusion, coronary sinus flow velocity recordings were re- 
peated. In case of anginal pain occurring during dipyridamole 
infusion, a bolus of aminophylline (0.12 to 0.24 g) was admin- 
istered intravenously. 
Coronary sinus flow velocity analysis and assessment of
coronary flow reserve. Videotape recordings of three cardiac 
cycles with optimal examination quality before and after 
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Figure 1. Modified transesophageal four-chamber view visualizing the 
coronary sinus (CS) draining into the right atrium (RA) with the 
Doppler sample volume placed in the position used for measurements. 
dipyridamole were analyzed. Measurements included maximal 
systolic and diastolic anterograde flow velocity, maximal retro- 
grade flow velocity and respective flow velocity time integrals. 
Net forward flow velocity time integral (VTInet) was calcu- 
lated by subtracting the retrograde from the anterograde flow 
velocity time integral, and VTInet x Heart rate was calculated 
as index of coronary sinus forward flow. Coronary flow reserve 
was defined as (VTInet x Heart rate) dipyridamole/(VTInet × 
Heart rate) baseline. On the basis of previously defined cutoff 
value, a coronary flow reserve >1.8 was considered normal (8). 
Coronary flow reserve was additionally calculated from the 
anterograde flow velocity time integral and maximal antero- 
grade flow velocitity, using the respective dipyridamole/rest 
ratios. 
Statistical analysis. Data are expressed as mean value _+ 
SD. To compare data of various patient groups, analysis of 
variance with a subsequent Scheff6 F test for multiple compar- 
isons was performed. Analysis of variance for repeated mea- 
sures was used to compare data before and after dipyridamole 
infusion. Statistical significance was considered at p < 0.05. 
The coronary flow reserve cutoff value of 1.8 was tested for 
sensitivity and specificity in patients with syndrome X and 
those with coronary artery disease. 
Results  
Clinical and hemodynamic data before and after dipyri. 
damole infusion. Hemodynamic data before and after dipyri- 
damole administration are presented in Table 2. Dipyridamole 
provoked chest pain in 4 of 9 patients with syndrome X and 3 
of 14 patients with coronary artery disease. In one patient with 
syndrome X and two with coronary artery disease, aminophyl- 
line had to be administered for prompt relief of symptoms. 
Coronary sinus Doppler measurements before and after 
dipyridamole. Overall, adequate coronary sinus flow velocity 
tracings could be obtained in 44 (97.7%) of 45 consecutive 
patients. Alignment of the Doppler beam and coronary sinus 
long axis could not be achieved in one control patient. An 
example of a coronary sinus Doppler recording is shown in 
Figure 2. Typically, a biphasic anterograde flow pattern and 
short mid- or end-diastolic periods of retrograde flow, or both, 
were observed. An example of a marked flow velocity increase 
after dipyridamole infusion in a healthy control patient is 
presented in Figure 3. By contrast, Figure 4 shows only a minor 
change in the coronary sinus flow velocity pattern in a patient 
with syndrome X. 
Table 3 presents various Doppler variables in the three 
patient groups at rest and after dipyridamole infusion. After 
dipyridamole infusion, variables of coronary sinus forward flow 
increased in most patients. However, changes from baseline 
markedly differed in the three patient groups: Increase in 
anterograde flow variables was significantly lower in patients 
with syndrome X and those with coronary artery disease 
compared with control patients. Retrograde flow variables as 
well as coronary sinus diameter emained unchanged in all 
patient groups after dipyridamole administration. 
Coronary flow reserve. Coronary flow reserve as calculated 
from net forward flow velocity time integral measurements 
before and after dipyidamole was 1.21 _+ 0.23 in patients with 
syndrome X and 1.47 _+ 0.7 in those with coronary artery 
disease (Fig. 5). This was significantly lower than the coronary 
flow reserve of 2.78 _+ 0.95 found in the control group (p < 
0.001 for both patient groups). Coronary flow reserve tended 
to be lower in patients with more severe coronary artery 
disease (group B1) than in group B2 with less severe disease 
(1.43 _--- 0.26 vs. 1.76 _+ 0.94, p = NS). 
Table 2. Hemodynamic Data Before and After Dipyridamole Administration for the Three 
Patient Groups 
Patients With 
Syndrome X Patients With CAD Control Patients 
Rest DPM Rest DPM Rest DPM 
HR (beats/rain) 91 + 15 96 _+ 16 74 _+ 18" 87 _+ 19t 81 _+ 13 97 _+ 17t 
Blood pressure (ram Hg) 
Systolic 147 z 13 153 + 20 155 _+ 23 148 + 23 147 _+ 2 142 _+ 225 
Diastolic 83 -+ 10 87 -+ 8 82 -+ 9 81 -+ 10 83 -+ 13 79 -+ 11~ 
Mean 104 _+ ll) 109 + 1I 106 + 12 103 + 13 104 + 15 100 + 13§ 
*p -< 0.05, syndrome X versus coronary arteff disease (CAD). tp -< 0.001, :]:p <- 0.05, §p < 0.005, rest versus 
dipyridamole (DPM). Data presented are mean value +_ SD. HR - heart rate. 
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Figure 2. Transesophageal Doppler flow velocity tracing of coronary 
sinus flow, characterized by biphasic systolic (SYS.) and diastolic 
(DIA.) anterograde flow and a short period of end-diastolic retrograde 
(RET.) flow. ECG = electrocardiogram. 
The predefined coronary flow reserve value of 1.8 allowed 
excellent differentiation of patients with syndrome X and with 
significant coronary artery disease from control patients (Table 
4). All patients with syndrome X had a coronary flow re- 
serve <1.8 (sensitivity 100%), whereas 20 of 22 patients 
without cardiac disease were found to have a flow reserve >1.8 
(specificity 91%). In patients with coronary artery disease, 12 
of 14 presented with a coronary flow reserve <1,8 (sensitivity 
86%). Coronary flow reserve was <1.8 in seven of seven 
patients in group BI and five of seven patients in group B2. 
Coronary flow reserve was 1.35 _+ 0.24 in patients with chest 
pain after dipyridamole infusion (four with syndrome X and 
three with coronary artery disease) and was 1.52 _+ 0.68 in 
asymptomatic patients in groups A and B (p = NS). 
Using the anterograde flow velocity time integral for coro- 
nary flow reserve calculation, coronary flow reserve was 2.28 _+ 
0.74 in control patients, 1.23 + 0.22 in patients with syn- 
drome X (p < 0.001 vs. control patients), and 1.40 _+ 0.66 in 
patients with coronary artery disease (p < 0.001 vs. control 
patients), yielding a sensitivity and specificity of 100% and 77% 
and 91% and 77% in patients with syndrome X and those with 
coronary artery disease, respectively. Using the maximal an- 
terograde flow velocity, coronary flow reserve was 1.82 _+ 0.76 
in control patients, 1.17 + 0.20 in syndrome X (p < 0.001 vs. 
control patients) and 1.35 _+ 0.25 in those with coronary artery 
disease, yielding a sensitivity of 100% in patients with syn- 
drome X and those with coronary artery disease at a lower 
specificity of 50%. 
Discuss ion 
Transesophageal Doppler ecordings of coronary sinus flow 
velocity before and after dipyridamole administration may 
Figure 3. Coronary sinus flow velocity recording ina control patient 
with normal coronary flow reserve. After dipyridamole (DPM) admin- 
istration, amarked increase inflow velocity occurs. ECG = electro- 
cardiogram. 
offer noninvasive assessment of coronary flow reserve. Initial 
results demonstrated the feasibility and reproducibility of this 
method in a large proportion of patients (8). The present study 
extends these preliminary findings by evaluating the diagnostic 
accuracy of the method in patients with syndrome X and those 
with significant left coronary artery disease. 
Various coronary sinus Doppler variables were evaluated 
for calculation of coronary flow reserve: Among the variables 
tested, net forward flow velocity time integral (i.e., anterograde- 
retrograde flow velocity time integral) times heart rate may 
best represent coronary sinus forward flow per time unit. 
However, the retrograde Doppler signal may not only repre- 
sent left coronary artery drainage but also may result from 
reflux of right atrial blood into the compliant coronary sinus 
due to increasing right atrial pressure during the cardiac ycle 
(14). Accordingly, in the present study retrograde flow vari- 
ables remained unchanged after dipyridamole administration. 
Assessment of coronary flow reserve by less complex antero- 
grade flow variables, uch as the anterograde flow velocity time 
integral or the maximal anterograde flow velocity, also enabled 
classification of different patient groups, but diagnostic accu- 
racy was lower. 
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Figure 5. Coronary flow reserve (CFR) in control patients and those 
with syndrome X and coronary artery disease (CAD). 
Figure 4. Coronary sinus flow velocity recording in a patient with 
syndrome X. Flow velocity is not significantly altered by dipyridamole 
(DPM) administration. ECG = electrocardiogram. 
Determination of coronary flow reserve in syndrome X. A 
reduced coronary flow reserve in patients with typical angina 
and a normal coronary angiogram constitutes an essential clue 
for the diagnosis of syndrome X (15,16). Previous tudies using 
the coronary sinus thermodilution technique reported mean 
coronary flow reserve values of 1.5 (range 1.2 to 2.1) in patients 
with syndrome X and 2.4 (range 2.0 to 2.9) in control patients 
(17-21). Slightly higher values were achieved using positron 
emission tomography (22,23) or intracoronary Doppler cathe- 
ters (4,13). Transesophageal Doppler recordings of proximal 
left anterior descending coronary artery flow velocity may also 
be applied for assessment of coronary flow reserve, but as a 
result of cardiac motion and the small diameter of the vessel 
examined, adequate flow signals could be achieved by this 
method in only 70% of patients (24). 
In the present study, transesophageal coronary sinus Dopp- 
ler recordings enabled assessment of coronary flow reserve in 
>90% of patients. Patients with syndrome X were found to 
Table 3. Doppler Echocardiographic Data Before and After Dipyridamole Administration for the 
Three Patient Groups 
Patients With Syndrome X Patients With CAD Control Patients 
Rest DPM Rest DPM Rest DPM 
Max flow velocity (cm/s) 
Systolic 44 ± 21 55 _+ 24* 32 ± 
Diastolic 42 ± 17 48 _+ 16 39 ± 
Retrograde 31 ± 15 31 ± 14 21 + 
Flow VTI 
Systolic 54 = 29 68 _+ 31 48 
Diastolic 75 ± 35 83 ± 42 69 + 
Retrograde 31 ± 20 34 _+ 21 29 _+ 
Anterograde 135 _+ 191 ~ 157 _+ 35 116 + 
Net 104 ± 2611 123 ± 40 87 + 
Net VTI × HR 975 = 298¶ 1,175 + 392* 629 = 
CSdiam (ram) 9 _+ 3 9 _+ 4 10 _+ 
15 52 ± 31" 38 ± 19 66 ± 27"~ 
16 40 ± 14~ 30 ± 9 53 ± 17§ 
13 23 ± 15 23 + 10 25 ± 15 
23 65 ± 49 48 _+ 24 93 _+ 47§ 
29 78 + 31 52 -+ 23 87 ± 32§ 
21 25 + 23 27 ± 19 33 _+ 31 
27 144 - 77 100 ± 32 187 + 51§ 
28 118±82 73±26 154_+45§ 
209# 1,001 ÷ 623* 581 = 210 1,483 ± 416§ 
2 11_+4 9±3 9_+2 
*p -< 0.05, ip < 0.01, §p < 0.001, rest versus dipyridamole (DPM) administration. ~:p -< 0.05, control patients versus 
those with coronary artery disease (CAD). J[p -< 0.05, ¶p < 0.001, control patients versus those with syndrome X. #p -< 
0.005, patients with syndrome X versus those with coronary after, disease. Data presented are mean value -+ SD. 
CSdiam = coronary sinus diameter; HR - heart rate; Max = maximal; VTI = flow velocity time integral. 
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Table 4. Sensitivity and Specificity ofCorona~ Flow 
Reserve Determinations 
Variable Syndrome X CAD 
Sensitivity 9/9 (100%) 12/14 (86%) 
Specificity 20/22 (91%) 20/22 (91%) 
PPV 9/11 (82%) 12/14 (86%) 
NPV 20/20 (100%) 20/22 (91%) 
OPV 29/31 (94%) 32/36 (89%) 
Data presented are number of patients (sensitivity). Results are calculated 
for a cutoff coronary flow reserve of 1.8. CAD = coronary, artery, disease; NPV 
(OPV, PPV) = negative (overall, positive) predictive value. 
have a significantly reduced coronary flow reserve compared 
with that in the control group (1.21 2 0.23 vs. 2.78 2 0.95, p < 
0.001) (Fig. 5). Applying a previously defined cutoff value for a 
normal coronary flow reserve >1.8 (8), all patients with 
syndrome X had a reduced coronary flow reserve. Conversely, 
coronary flow reserve was >1.8 in 20 of 22 control patients. 
Determination of coronary flow reserve in coronary artery 
disease. In the present group of patients with significant left 
coronary artery disease, coronary flow reserve was significantly 
attenuated compared with that in the control group (1.47 _+ 0.7 
vs. 2.78 _+ 0.95, p -< 0.001). However, coronary flow reserve 
ranged considerably from 0.82 to 3.5, which may be explained 
by the variable degrees of stenoses as well as by the inability of 
coronary angiography to adequately assess the physiologic 
severity of stenosis (25-27). In addition, coronary sinus flow 
results from drainage of both the left anterior and circumflex 
coronary artery territory. Therefore, coronary flow reserve 
calculation based on coronary sinus flow constitutes the aver- 
age flow reserve of the left coronary system. Presence of an 
isolated or more distal stenosis within the left coronary artery 
may therefore have only a limited effect on coronary flow 
reserve calculation based on coronary sinus flow (28). Never- 
theless, 12 of 14 patients with coronary artery disease had a 
coronary flow reserve < 1.8. Moreover, all patients with severe 
proximal stenosis of the left anterior descending coronary 
artery had a reduced coronary flow reserve <1.8; only two 
patients with less severe stenosis had a coronary flow reserve 
>1.8. 
Study limitations. Although transesophageal chocardiog- 
raphy is generally considered a noninvasive technique, it is 
associated with minimal discomfort and risk to the patient 
(29). Hyperkinetic cardiac motion, malalignment of the ultra- 
sound beam with the coronary sinus long axis or a patient's 
inability to hold their breath may eventually prevent adequate 
Doppler ecordings. 
Regional coronary flow reserve cannot be determined by 
transesophageal coronary sinus flow velocity recordings. 
Therefore, this method may be insensitive for the detection of 
distal or side branch stenoses and will not provide information 
about he location of a stenosis. Because of the physiology of 
coronary venous drainage, coronary flow reserve calculations 
are limited to the territory of the left coronary artery. These 
limitations are shared by other techniques u ing coronary sinus 
flow measurements for the calculation of coronary flow re- 
serve. However, in cardiac disease with diffuse reduction of 
coronary flow reserve, evaluation of global flow reserve by 
coronary sinus techniques may be even more appropriate. 
Quantitative flow measurements cannot be achieved by 
Doppler techniques without he additional measurement of 
the cross-sectional area of the interrogated vessel. We did not 
incorporate coronary sinus diameter measurements into the 
present method because the diameter of the coronary sinus 
may change considerably throughout the cardiac ycle. There- 
fore, coronary flow reserve was derived from the comparison of 
flow velocity recordings before and after dipyridamole admin- 
istration, which is based on the presence of a constant diameter 
of the coronary sinus during vasodilator application. To mini- 
mize potential errors resulting from different angulations 
between the ultrasound beam and the coronary sinus, the 
transducer p obe was kept in identical position throughout the 
study period. Nevertheless, adherence to a strict examination 
protocol as well as a learning curve experience are required to 
obtain reproducible results. 
The present control group was formed by otherwise healthy 
neurosurgical patients in whom preoperative transesophageal 
echocardiography was indicated to exclude the presence of a 
patent foramen ovale. These patients had normal ECG and 
echocardiographic findings, and major cardiovascular risk fac- 
tors were absent. However, coronary angiography was not 
performed in this group because it was not considered appro- 
priate in patients without cardiac symptoms. 
Clinical implications. Evaluation of coronary sinus flow 
velocity by transesophageal Doppler echocardiography before 
and after dipyridamole administration appears to be a feasible 
method for assessment ofcoronary flow reserve. Although the 
transesophageal xamination presents some discomfort to the 
patient and is associated with a minimal risk, it is less invasive, 
less time-consuming, and less expensive and requires less 
laboratory equipment and personnel than most previously used 
techniques. It can be performed on an ambulatory basis within 
reasonable time using routine echocardiographic equipment 
and can be applied in the majority of patients. 
The results of the present study suggest that evaluation of 
coronary sinus flow velocity by transesophageal Doppler echo- 
cardiography can be used to identify patients with syndrome X 
with high sensitivity once coronary artery disease has been 
excluded. 
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